Ek kim
global head of commercial biomarkers and diagnostics Amgen
EK Kim is the Global Head of Commercial Biomarkers and Diagnostics at Amgen, where she leads the commercialization and launch strategy for diagnostic and patient identification tools across oncology, cardiovascular, inflammation, and rare disease. She has held leadership roles across commercial and development functions and has directed global readiness for multiple integrated medicine and diagnostic launches. Prior to Amgen, EK held senior roles at AstraZeneca, Personal Genome Diagnostics (PGDx), Roche Diagnostics, and Ventana Medical Systems, where she advanced precision medicine strategies that supported global brand planning, development and regulatory planning, and commercialization.
Seminars
- What is the biggest barrier each stakeholder sees when drugs and diagnostics are developed or evaluated in silos, and how do we overcome these disconnects?
- When Rx-Dx don’t launch together, what are the downstream consequences for physicians, patients, and payers, and how can these be prevented?
- What lessons from HER2, EGFR, and PD-L1 can we apply today, and what pitfalls must be avoided as we move toward more complex biomarkers like multimodal and AI-driven diagnostics?
